Zilebesiran for High Blood Pressure

(KARDIA-3 Trial)

Recruiting at 164 trial locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: Alnylam Pharmaceuticals

Prior Safety Data

Trial Summary

What is the purpose of this trial?

The purpose of this study is to evaluate the effect of zilebesiran as add-on therapy in patients with high cardiovascular risk and hypertension not adequately controlled by standard of care antihypertensive medications.

Do I have to stop taking my current medications for this trial?

No, you must continue taking your current antihypertensive medications as the trial is testing zilebesiran as an add-on therapy.

What data supports the idea that Zilebesiran for High Blood Pressure is an effective drug?

The available research shows that Zilebesiran can effectively lower blood pressure. It has been shown to reduce systolic blood pressure by up to 20 mm Hg, and this effect lasts for six months after just one dose. This is a significant improvement compared to other treatments like IONIS-AGT-LRX, which had only a small effect on blood pressure. Additionally, Zilebesiran does not cause serious side effects like kidney injury, making it a promising option for managing high blood pressure. ^{1 2 3 4 5}

What safety data is available for Zilebesiran in treating high blood pressure?

Zilebesiran, a small-interfering RNA targeting liver angiotensinogen, has shown an impressive and durable effect on reducing systolic blood pressure by up to 20 mm Hg, sustained for 6 months after a single administration. Importantly, it does not cause acute kidney injury or hyperkalemia. Future studies are needed to evaluate long-term safety issues, such as the potential development of antidrug antibodies and the effects of prolonged angiotensinogen suppression. ^{1 6 7 8 9}

Is the drug Zilebesiran a promising treatment for high blood pressure?

Yes, Zilebesiran is a promising drug for high blood pressure. It can significantly lower blood pressure by up to 20 mm Hg and maintain this effect for six months after just one dose. This is achieved by targeting and reducing a specific protein in the liver that contributes to high blood pressure, without causing major side effects. ^{1 2 7 10 11}

Research Team

Medical Director

Principal Investigator

Alnylam Pharmaceuticals

Eligibility Criteria

This trial is for adults with high blood pressure not well-managed by 2-4 standard medications and who have a history of heart disease or are at high risk for it. They should have specific blood pressure readings and a moderately reduced kidney function but not severe kidney issues.

Inclusion Criteria

24-hour mean SBP ≥130 mmHg and ≤170 mmHg assessed by ABPM

I am taking 2 to 4 different blood pressure medications without recent changes.

Mean seated office SBP ≥140 mmHg and ≤170 mmHg

Exclusion Criteria

Proteinuria >3 g/day

Serum potassium >4.8 mEq/L

I experience significant drops in blood pressure when standing up.

Treatment Details

Interventions

• Zilebesiran (Antisense Oligonucleotide)

Trial Overview The study tests Zilebesiran, added to usual blood pressure meds, against a placebo. It aims to see if Zilebesiran better controls blood pressure in those at high risk for heart problems.

Participant Groups

Group I: Zilebesiran Experimental Treatment 1 Intervention

Participants will receive zilebesiran on Day 1 of the 6-month double-blind (DB) treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.

Group II: Placebo Placebo Group 1 Intervention

Participants will receive placebo on Day 1 of the 6-month DB treatment period. Participants must be on stable doses of at least 2, but not more than 4, antihypertensive medications for at least 30 days prior to screening and plan to remain on stable doses of these medications during screening and through the DB treatment period.

Who Is Running the Clinical Trial?

Alnylam Pharmaceuticals

Lead Sponsor

Trials

81

Recruited

16,100+

Dr. Yvonne Greenstreet

Alnylam Pharmaceuticals

Chief Executive Officer since 2021

MD from the University of Leeds, MBA from INSEAD

Dr. Pushkal Garg

Alnylam Pharmaceuticals

Chief Medical Officer since 2016

MD from Columbia University

Findings from Research

Zilebesiran, a novel RNA therapeutic, effectively reduces systolic blood pressure by up to 20 mm Hg and maintains this effect for 6 months after a single dose, by targeting and silencing angiotensinogen in the liver.

In contrast, IONIS-AGT-LRX showed less effectiveness in lowering blood pressure, highlighting zilebesiran's superior ability to manage hypertension without causing significant side effects like acute kidney injury or hyperkalemia.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics. Addison, ML., Ranasinghe, P., Webb, DJ.[2023]

Gene therapy has shown promise in reducing blood pressure (BP) by 10-30 mmHg in experimental studies involving 63 studies on small rodents, targeting various systems related to hypertension.

Despite these encouraging results, gene therapy for hypertension has not yet progressed to clinical trials, highlighting the need for improved gene transfection methods and further research in larger mammals before it can compete with existing treatments.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Gene therapy for hypertension. Paulis, L., Franke, H., Simko, F.[2018]

Targeting hepatic angiotensinogen (AGT) with small interfering RNA (siRNA) presents a promising new strategy for managing hypertension, potentially overcoming issues like poor patient adherence and the RAS escape phenomenon.

This approach could allow for infrequent dosing (1 to 2 times per year) while effectively blocking the renin-angiotensin system, as shown in preclinical models and the initial human study, suggesting a significant advancement in hypertension treatment.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Targeting Angiotensinogen With N-Acetylgalactosamine-Conjugated Small Interfering RNA to Reduce Blood Pressure. Ye, D., Cruz-López, EO., Tu, HC., et al.[2023]

In a study of 212 untreated hypertensive Caucasian individuals, specific AGT gene variants (-532T and -6A) were linked to significantly higher blood pressure levels, indicating their potential role in hypertension.

Haplotype analysis of the AGT gene revealed that different combinations of alleles at positions -532 and -6 were associated with varying blood pressure values, suggesting that understanding these haplotypes could enhance our knowledge of genetic influences on blood pressure regulation.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. Brand-Herrmann, SM., Köpke, K., Reichenberger, F., et al.[2022]

In a study of 50 patients with renoparenchymal hypertension due to chronic pyelonephritis, Candesartan effectively controlled arterial pressure, achieving target levels in 94.3% of patients over 12 months.

The clinical effectiveness of Candesartan was consistent across different genetic variants of the angiotensin II receptor gene, indicating its broad applicability in treating this condition.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

[Pharmacogenetic aspects of candesartan application for the treatment of arterial hypertension in patients with chronic pyelonephritis]. Mormol', IA.[2021]

In a 24-week study involving 421 elderly patients with isolated systolic hypertension, valsartan demonstrated similar blood pressure-lowering efficacy compared to amlodipine, but with significantly fewer adverse effects.

Valsartan had a lower overall adverse event rate (20.2%) compared to amlodipine (31.9%), particularly showing a much lower incidence of peripheral edema (4.8% for valsartan vs. 26.8% for amlodipine), indicating better tolerability for valsartan in this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. Malacco, E., Varì, N., Capuano, V., et al.[2019]

In a study of 84 patients, both olmesartan and azilsartan effectively reduced blood pressure over 16 weeks, with no significant differences in efficacy between the two medications.

Both drugs were well tolerated and showed similar safety profiles, with no major adverse events reported, indicating they are safe options for managing hypertension.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study). Kakio, Y., Uchida, HA., Umebayashi, R., et al.[2022]

Azilsartan effectively reduced systolic blood pressure in both elderly patients (≥65 years) and younger patients (<65 years) after 12 weeks of treatment, with no significant differences in blood pressure reduction between the two age groups.

The treatment with azilsartan was found to be safe, as there were no adverse changes in clinical laboratory findings, indicating it could be a valuable option for managing hypertension in both elderly and non-elderly patients.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension. Kamada, T., Hayashi, M., Fujiwara, W., et al.[2019]

Irbesartan, an angiotensin II receptor blocker, was found to be well tolerated in a study involving 1,965 patients over 4 to 12 weeks, with no evidence of dose-related adverse effects.

Compared to placebo, irbesartan showed a lower incidence of adverse events and serious adverse events, indicating a safety profile similar to that of a placebo, with no significant changes in laboratory results or rebound hypertension upon withdrawal.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Safety of irbesartan in the treatment of mild to moderate systemic hypertension. Simon, TA., Gelarden, RT., Freitag, SA., et al.[2019]

In a 16-week study involving 622 Japanese patients with grade I-II essential hypertension, azilsartan (20-40 mg) significantly reduced diastolic blood pressure by -12.4 mm Hg compared to -9.8 mm Hg with candesartan (8-12 mg), showing a greater efficacy (difference of -2.6 mm Hg, P=0.0003).

Azilsartan also demonstrated a more significant reduction in systolic blood pressure (-21.8 mm Hg) compared to candesartan (-17.5 mm Hg), with similar safety profiles for both medications, indicating azilsartan's potential as a more effective treatment for hypertension.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. Rakugi, H., Enya, K., Sugiura, K., et al.[2022]

In a study of 60 outpatients post-cardiac surgery, olmesartan was found to be more effective than azilsartan in reducing levels of angiotensin II and aldosterone after one year of treatment.

Patients taking olmesartan required fewer additional antihypertensive medications compared to those on azilsartan, indicating better blood pressure control and potentially greater efficacy in managing hypertension.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). Sezai, A., Osaka, S., Yaoita, H., et al.[2019]

References

1. United States pubmed.ncbi.nlm.nih.gov

Novel Pharmacological Approaches in the Treatment of Hypertension: A Focus on RNA-Based Therapeutics. [2023]

2. England pubmed.ncbi.nlm.nih.gov

Gene therapy for hypertension. [2018]

3. United States pubmed.ncbi.nlm.nih.gov

Targeting Angiotensinogen With N-Acetylgalactosamine-Conjugated Small Interfering RNA to Reduce Blood Pressure. [2023]

4. Netherlands pubmed.ncbi.nlm.nih.gov

Angiotensinogen promoter haplotypes are associated with blood pressure in untreated hypertensives. [2022]

5. Ukraine pubmed.ncbi.nlm.nih.gov

[Pharmacogenetic aspects of candesartan application for the treatment of arterial hypertension in patients with chronic pyelonephritis]. [2021]

6. United States pubmed.ncbi.nlm.nih.gov

A randomized, double-blind, active-controlled, parallel-group comparison of valsartan and amlodipine in the treatment of isolated systolic hypertension in elderly patients: the Val-Syst study. [2019]

7. England pubmed.ncbi.nlm.nih.gov

Practical efficacy of olmesartan versus azilsartan in patients with hypertension: a multicenter randomized-controlled trial (MUSCAT-4 study). [2022]

8. United States pubmed.ncbi.nlm.nih.gov

Antihypertensive efficacy and safety of the angiotensin receptor blocker azilsartan in elderly patients with hypertension. [2019]

9. United States pubmed.ncbi.nlm.nih.gov

Safety of irbesartan in the treatment of mild to moderate systemic hypertension. [2019]

10. England pubmed.ncbi.nlm.nih.gov

Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study. [2022]

11. Japan pubmed.ncbi.nlm.nih.gov

Changeover Trial of Azilsartan and Olmesartan Comparing Effects on the Renin-Angiotensin-Aldosterone System in Patients with Essential Hypertension after Cardiac Surgery (CHAOS Study). [2019]